Avandia & Congestive Heart Failure

On August 14 th , 2007 the U.S. Food and Drug Administration announced manufacturers of certain drugs approved to treat Type 2 diabetes, including Avandia, have agreed to add a stronger warning on the risk of heart failure, a condition that occurs when the heart does not adequately pump blood. The information will be included in the form of a "boxed" warning?FDA's strongest form of a warning. The upgraded warning emphasizes that the drugs may cause or worsen heart failure in certain patients.

"Under FDA's postmarketing surveillance program, we carefully monitor new safety information for marketed drugs and take appropriate action when necessary to inform patients and health care providers of new information," said Steven Galson, M.D., M.P.H., director of FDA's left for Drug Evaluation and Research. "This new boxed warning addresses FDA's concerns that despite the warnings and information already listed in the drug labels, these drugs are still being prescribed to patients without careful monitoring for signs of heart failure."

FDA's review of adverse event reports found cases of significant weight gain and edema?warning signs of heart failure. In some reports, FDA noted, continuation of therapy has been associated with poor outcomes, including death.

The strengthened warning advises health care professionals to observe patients carefully for the signs and symptoms of heart failure, including excessive, rapid weight gain, shortness of breath, and edema after starting drug therapy. Patients with these symptoms who then develop heart failure should receive appropriate management of the heart failure and use of the drug should be reconsidered. People who have questions should contact their health care providers to discuss alternative treatments.

The warning also states that these drugs should not be used by people with serious or severe heart failure who have marked limits on their activity and who are comfortable only at rest or who are confined to bed or a chair.

FDA's review of Avandia and possible increased risk of heart attacks is ongoing. On July 30, 2007 , FDA's Endocrine and Metabolic Advisory Committee and the Drug Safety and Risk Management Advisory Committee recommended that Avandia continue to be marketed, and further recommended that information be added to the labeling for risk of heart attacks (ischemic risks).

1.) Have you or a loved one used Avandia?
2.) Have you or a loved one suffered any of the following injuries?
Heart Attack
Stroke
Heart Failure
Death
Heart Stent/Pacemaker installation
CABG Surgery/Coronary Bypass
Congestive Heart Failure
Congestive Heart Failure NOT while using Avandia
Macular Edema
Liver Failure
Other
3.) Do you already have an attorney representing you on this case?
Please provide details about this Case.

By leaving this box checked, I agree to receive future offers and announcements from Consumer Ally, LLC and its affiliates and partners.

Featured Lawsuits
THIS IS AN ADVERTISEMENT This website is not affiliated with any pharmaceutical or medical device company or any trademarked product. Results are not guaranteed. This website provides a free matching service and is not responsible for information or services from third party providers. An Attorney For You is an advertising group that represents lawyers, it is not a law firm or referral service. Every case is different and services available will vary depending on state.

Calliope Media, Inc. Copyright 2014 © All rights reserved.